Product Profiles: Depression - Next Generation Vies for Second-Line Patients

15 Jul 2011 • by Natalie Aster

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

The report “Product Profiles: Depression - Next Generation Vies for Second-Line Patients” by Datamonitor allows to:

  • Understand Datamonitor’s independent appraisal of marketed brands and key pipeline agents indicated for treating depression;
  • Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes;
  • Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data;
  • Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists;
  • Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Your key questions answered:

  • What is the gold-standard drug for depression?
  • How are marketed brands positioned in the depression treatment algorithm?
  • Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?
  • What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?

Report Details:

Product Profiles: Depression - Next Generation Vies for Second-Line Patients

Published: June 2011

Pages: 221

Price: US$ 11,400.00

Report Highlights

Datamonitor’s physician survey reveals that psychiatrists perceive Forest’s and Lundbeck’s selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.

Valdoxan (agomelatine; Servier/Novartis) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.

Forest’s Viibryd (vilazodone) has the hallmarks of a new blockbuster – a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

More information can be found in the report “Product Profiles: Depression - Next Generation Vies for Second-Line Patients” by Datamonitor.

To order the report or ask for sample pages contact  ps@marketpublishers.com

 

Contacts

MarketPublishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com